On November 18, Gelonghui announced that Baiyunshan (00874.HK) recently received a pharmaceutical production license approved and issued by the Guangdong Provincial Pharmaceutical Supervision Administration for its wholly-owned subsidiary, Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. (hereinafter referred to as "Mingxing Pharmaceutical"), which allows Mingxing Pharmaceutical to add new production workshops, production lines, and production scope, and has passed the compliance inspection of pharmaceutical production quality management standards.
It is agreed that Mingxing Pharmaceutical will add production workshops at the production address "99 Jianxu Third Road, Baiyun District, Guangzhou," new production workshops include "Manufacturing Department Six and Manufacturing Department Eight," new production lines include "small volume injectable (non-terminal sterilization) production line, small volume injectable (terminal sterilization) production line, freeze-dried powder injection production line," and new production scope includes "small volume injectable (non-terminal sterilization), small volume injectable (terminal sterilization), freeze-dried powder injection." Compliance inspections on the small volume injectable (non-terminal sterilization) production line and small volume injectable (terminal sterilization) production line in Manufacturing Department Six and the freeze-dried powder injection production line in Manufacturing Department Eight show that the inspection scope "small volume injectable (non-terminal sterilization), small volume injectable (terminal sterilization), freeze-dried powder injection" meets the requirements of the "Pharmaceutical Production Quality Management Standards (2010 revision)."
The addition of new production workshops, production lines, and production scope by Mingxing Pharmaceutical, along with passing the compliance inspection of pharmaceutical production quality management standards, will help optimize its capacity, enhance the levels of asia vets, digitalization, and greenness, maintain stable production capabilities, and meet market demands. The acquisition of the "Pharmaceutical Production License" will not have a significant impact on the company's current performance.
